Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Rheumatology (Oxford, England)|October 5, 2023
Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis populationCalin D Popa, Merel A A Opdam, Nathan den Broeder, et al.
Clinical Pharmacology and Therapeutics|October 23, 2025
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do MatterAmy C D Peeters, Maike H M Wientjes, Wieland D Müskens, et al.
Trials|June 20, 2021
Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trialMaike H M Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, et al.
Rheumatology (Oxford, England)|December 20, 2022
The added value of predictive biomarkers in treat-to-target strategies for rheumatoid arthritis patients: a conceptual modelling studyMaike H M Wientjes, Evy Ulijn, Wietske Kievit, et al.
European Journal of Preventive Cardiology|August 13, 2025
Ischaemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological studyIris Rose Peeters, Maike H M Wientjes, Isla S Mackenzie, et al.
Annals of the Rheumatic Diseases|May 3, 2025
Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trialMaike H M Wientjes, Sadaf Atiqi, Gerrit J Wolbink, et al.
Pageof 2